Value Investor
Start free

Scholar Rock Holding

SRRK on Nasdaq. Scholar Rock makes medicines for people with spinal muscular atrophy and other muscle diseases. Market value $5.3bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-5.6%low

For every $100 of what the whole company costs, it produced $-5.62 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-82.7%five-year median

Each dollar kept in the business earns -83 cents a year. Above 10 is good.

Quality score: 30 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$43.40 a share, 60% above its 1-year low

Over the past year the price has ranged from $27.07 to $61.76.

Pays no dividend

Prices from Monday’s close (5 October).

Five years of cash, in billions

-0.1
-0.1
-0.1
-0.2
-0.3
-0.3
2021202220232024202512 monthsto Jun '26
Revenue
$19m$33mn/an/a$0
Operating margin
-690.5%-404.8%n/an/an/a
Debt to equity
0.310.200.230.140.41
Shares outstanding
0.05bn0.07bn0.09bn0.10bn0.12bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)1 of 7 checks we could run
  • Profit backed by cash (accruals)No
  • Debt0.41× equity
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 136% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $110 million, compared with a loss of $110 million a year ago.
  • Over the past 12 months it spent $297 million more cash than it brought in, compared with $258 million a year earlier.
  • 16% more shares than a year ago. Each share owns a bit less of the company.
  • It has $241 million more cash than debt, up from $103 million a year ago.
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$64m
December 2024-$66m
March 2025-$75m
June 2025-$110m
September 2025-$102m
December 2025-$91m
March 2026-$106m
June 2026-$110m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
3 March 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

2 long-term investors we follow own it, unchanged from 2 last quarter. 306 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • FMR LLC
    Passive investor
    at least 15.0%
    (filed with 1 related holder)
    Since 31 December 2024
  • Invus Public Equities, L.P.
    Passive investor
    at least 8.0%−3.4 pts
    (filed with 4 related holders)
    Since 30 June 2026
  • Srinivas Akkaraju
    Passive investor
    at least 7.2%
    (filed with 4 related holders)
    Since 3 October 2025
  • at least 5.6%
    (filed with 3 related holders)
    Since 31 December 2025
  • 5.4%−1.8 pts
    Since 31 March 2026
  • Redmile Group, LLC
    Passive investor
    at least 3.6%−4.0 pts
    (filed with 2 related holders)
    Since 30 June 2026
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $1m of shares on the open market. 13 sold $19m, $9m of it under preset trading plans.

  • FLIER JEFFREY S.
    Director
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    3,053
    Price
    $53.88
    Value
    $164,490
  • Gilman Michael
    Director
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    2,544
    Price
    $53.88
    Value
    $137,058
  • Burow Kristina
    Director
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    3,053
    Price
    $53.74
    Value
    $164,064
  • Reed Joshua
    Director
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    3,053
    Price
    $53.74
    Value
    $164,067
  • Peng Katie
    Director
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    5,446
    Price
    $53.88
    Value
    $293,405
  • Woods Keith
    Chief Operating Officer
    Sold
    Date
    16 April 2026
    Shares
    10,220
    Price
    $49.57
    Value
    $506,605
  • Vaishnaw Akshay
    President of R&D, Director
    Sold
    Date
    16 April 2026
    Shares
    12,246
    Price
    $49.57
    Value
    $607,034
  • Sinha Vikas
    Chief Financial Officer
    Sold
    Date
    16 April 2026
    Shares
    10,410
    Price
    $49.57
    Value
    $516,024
  • Hallal David
    Chief Executive Officer, Director
    Sold
    Date
    16 April 2026
    Shares
    30,615
    Price
    $49.57
    Value
    $2m
  • Qatanani Mo
    CHIEF SCIENTIFIC OFFICER
    Sold
    under a preset trading plan
    Date
    23 February 2026
    Shares
    8,484
    Price
    $47.07
    Value
    $399,335

From Form 4 filings: insiders must report trades in their own company's shares within two days.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.